115724-21-5

Basic information

• Product Name: MOBS
• Synonyms: TIMTEC-BB SBB009134;MOBS;4-(N-MORPHOLINO)BUTANESULFONIC ACID;4-Morpholinebutanesulfonicacid;4-morpholin-4-ylbutane-1-sulfonic acid;4-Morpholinobutane-1-sulfonic acid
• CAS NO: 115724-21-5
• Molecular Formula: C8H17NO4S
• Molecular Weight: 223.29
• Mol File: 115724-21-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Water Solubility: Soluble in water.
• CAS DataBase Reference: MOBS(CAS DataBase Reference)
• NIST Chemistry Reference: MOBS(115724-21-5)
• EPA Substance Registry System: MOBS(115724-21-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 115724-21-5(Hazardous Substances Data)

Usage

Uses

Used in Biology and Biochemistry:
MOBS is used as a buffering agent for maintaining stable pH levels in various biological and biochemical applications. Its zwitterionic nature minimizes interactions with biomolecules, ensuring that the buffered solutions do not interfere with the intended experiments or processes.
Used in Polyacrylamide Gel Electrophoresis:
In the field of molecular biology, MOBS is widely used for polyacrylamide gel electrophoresis, a technique employed to separate proteins or nucleic acids based on their size and charge. The buffering capacity of MOBS helps maintain a consistent pH environment, allowing for accurate and reliable separation of biomolecules.
Used in Mammalian Cell Culture (with caution):
While MOBS can be used in mammalian cell culture, its usage is not recommended above 20 mM due to potential adverse effects on cell growth and function. At lower concentrations, MOBS can still provide the necessary buffering capacity without negatively impacting cell culture work.

Upstream product

• 110-91-8 morpholine 
• 1633-83-6 1,4-butane sultone 

Relevant articles and documents

Recyclable supported Br?nsted acidic ionic liquid catalysts with non-aromatic cations for the oligomerization of isobutene under mild conditions

Br?nsted acidic ionic liquids with different type of cations (pyridinium, morpholinium, pyrrolidinium, imidazolium), N-sulfoalkyl chain length and different anions (triflate, hydrogensulfate and tetrafluoroborate) were prepared and immobilised on silica by adsorption. The ionic liquids were characterised by NMR and IR. Surface properties and Br?nsted/Lewis acidity of the supported catalysts were also determined. Their catalytic activity and recyclability were compared in the oligomerisation of isobutene to obtain products that can be used as jet fuel blending components after hydrogenation. The results proved that imidazolium ionic liquids can be replaced by less toxic non-aromatic versions without any loss in their activity and stability. By the introduction of shorter sulfoalkyl chain into the cation, excellent results could be obtained even under milder conditions (lower temperature and shorter reaction time). Catalytic activity was shown to correlate to the Br?nsted acidity of the catalyst.

New Br?nsted-Lewis acidic quaternary ammonium ionic liquids: Synthesis, acidity determination and acidity-catalytic activity relationship

A series of new Br?nsted-Lewis acidic ionic liquids, which are operational simplicity, high stability, low cost and applicable for scaling up, have been synthesized and their activity for acetalization was examined. The comprehensive studies on the acidity-catalytic performance relationship of the Br?nsted-Lewis acidic ionic liquids were performed. IR spectroscopy results confirmed that the new Br?nsted-Lewis acidic ionic liquids possess both Br?nsted and Lewis acid sites. The acidities were determined by Hammett method, and further studies on acidity-activity relationship revealed that the acidity played a key role in the acid-catalyzed probe reactions.

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

There are described according to the invention compounds of formula (I) (relative stereochemistry indicated), wherein R1, R2, R3 and X are as defined in the specification, together with processes for preparing them, compositions containing them and their use as pharmaceuticals. Compounds of formula (I) are indicated inter alia for the treatment of chronic bronchitis.